HomeCompareHOLX vs WAB

HOLX vs WAB: Dividend Comparison 2026

HOLX yields 2.65% · WAB yields 0.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WAB wins by $459.4K in total portfolio value· pulled ahead in Year 4
10 years
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →
WAB
WAB
● Live price
0.45%
Share price
$237.37
Annual div
$1.06
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$483.0K
Annual income
$337,751.90
Full WAB calculator →

Portfolio growth — HOLX vs WAB

📍 WAB pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOLXWAB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOLX + WAB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOLX pays
WAB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
WAB
Annual income on $10K today (after 15% tax)
$37.96/yr
After 10yr DRIP, annual income (after tax)
$287,089.12/yr
At 15% tax rate, WAB beats the other by $286,822.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOLX + WAB for your $10,000?

HOLX: 50%WAB: 50%
100% WAB50/50100% HOLX
Portfolio after 10yr
$253.3K
Annual income
$169,032.96/yr
Blended yield
66.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on WAB right now

HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
WAB
Analyst Ratings
21
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$277.80
+17.0% upside vs current
Range: $221.00 — $315.00
Altman Z
3.3
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOLX buys
0
WAB buys
0
No recent congressional trades found for HOLX or WAB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOLXWAB
Forward yield2.65%0.45%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%100%
Portfolio after 10y$23.6K$483.0K
Annual income after 10y$314.03$337,751.90
Total dividends collected$2.9K$450.4K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$77.80$277.80

Year-by-year: HOLX vs WAB ($10,000, DRIP)

YearHOLX PortfolioHOLX Income/yrWAB PortfolioWAB Income/yrGap
1$10,965$264.73$10,789$89.31+$176.00HOLX
2$12,004$271.27$11,725$180.12+$279.00HOLX
3$13,121$277.55$12,911$365.85+$210.00HOLX
4← crossover$14,323$283.54$14,568$753.04$245.00WAB
5$15,615$289.27$17,176$1,588.17$1.6KWAB
6$17,003$294.73$21,878$3,499.96$4.9KWAB
7$18,493$299.93$31,743$8,332.99$13.3KWAB
8$20,093$304.87$56,563$22,598.44$36.5KWAB
9$21,809$309.57$135,791$75,268.61$114.0KWAB
10$23,649$314.03$483,049$337,751.90$459.4KWAB

HOLX vs WAB: Complete Analysis 2026

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →

WABStock

Westinghouse Air Brake Technologies Corporation provides technology-based equipment, systems, and services for the freight rail and passenger transit industries worldwide. It operates through two segments, Freight and Transit. The Freight segment manufactures and services components for new and existing freight cars and locomotives; builds new commuter locomotives; rebuilds freight locomotives; supplies railway electronics, positive train control equipment, signal design, and engineering services; and provides related heat exchange and cooling systems. It serves publicly traded railroads; leasing companies; manufacturers of original equipment, including locomotives and freight cars; and utilities. The Transit segment manufactures and services components for new and existing passenger transit vehicles, such as regional trains, high speed trains, subway cars, light-rail vehicles, and buses; refurbishes subway cars; and provides heating, ventilation, and air conditioning equipment, as well as doors for buses and subways. This segment serves public transit authorities and municipalities, leasing companies, and manufacturers of subway cars and buses. It also provides electronically controlled pneumatic braking products; railway electronics; freight car trucks; draft gears, couplers, and slack adjusters; air compressors and dryers; heat exchangers and cooling products; and track and switch products. In addition, the company offers railway braking equipment and related components; friction products; new switcher locomotives; transit locomotive and car overhaul services; and freight locomotive overhaul, modernizations, and refurbishment services. Further, it provides platform screen doors; pantographs; window assemblies; couplers; accessibility lifts and ramps for buses and subway cars; and traction motors. The company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania.

Full WAB Calculator →
📬

Get this HOLX vs WAB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOLX vs SCHDHOLX vs JEPIHOLX vs OHOLX vs KOHOLX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.